Interaction of HT with combination of GP1BA and GP6 genotypes for CHD risk
| Patient group by HT . | Patient genotype . | n . | Year 1 . | End of follow-up . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GP1BA . | GP6 . | No. . | Rate* . | HR (CI)† . | P‡ . | No. . | Rate* . | HR (CI)† . | P‡ . | ||
| Group 1 | TT | TT | 1.257 (0.73-2.17) | .004 | 1.02 (0.81-1.30) | < .001 | |||||
| N | 557 | 24 | 44.0 | — | — | 137 | 42.3 | — | — | ||
| Y | 579 | 29 | 51.74 | — | — | 144 | 42.8 | — | — | ||
| Group 2 | TT | TC/CC | 3.35 (1.4-8.03) | — | 1.57 (1.08-2.29) | — | |||||
| N | 232 | 8 | 35.02 | — | — | 49 | 35.88 | — | — | ||
| Y | 211 | 20 | 98.81 | — | — | 67 | 57.4 | — | — | ||
| Group 3 | TC/CC | TT | 0.3 (0.11-0.92) | — | 0.45 (0.28-0.70) | — | |||||
| N | 168 | 14 | 87.14 | — | — | 56 | 61.44 | — | — | ||
| Y | 183 | 6 | 33.39 | — | — | 32 | 28.77 | — | — | ||
| Group 4 | TC/CC | TC/CC | 1.37 (0.26-7.35) | — | 0.76 (0.4-1.44) | — | |||||
| N | 90 | 3 | 33.88 | — | — | 24 | 46.23 | — | — | ||
| Y | 70 | 3 | 43.59 | — | — | 17 | 39.84 | — | — | ||
| Patient group by HT . | Patient genotype . | n . | Year 1 . | End of follow-up . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GP1BA . | GP6 . | No. . | Rate* . | HR (CI)† . | P‡ . | No. . | Rate* . | HR (CI)† . | P‡ . | ||
| Group 1 | TT | TT | 1.257 (0.73-2.17) | .004 | 1.02 (0.81-1.30) | < .001 | |||||
| N | 557 | 24 | 44.0 | — | — | 137 | 42.3 | — | — | ||
| Y | 579 | 29 | 51.74 | — | — | 144 | 42.8 | — | — | ||
| Group 2 | TT | TC/CC | 3.35 (1.4-8.03) | — | 1.57 (1.08-2.29) | — | |||||
| N | 232 | 8 | 35.02 | — | — | 49 | 35.88 | — | — | ||
| Y | 211 | 20 | 98.81 | — | — | 67 | 57.4 | — | — | ||
| Group 3 | TC/CC | TT | 0.3 (0.11-0.92) | — | 0.45 (0.28-0.70) | — | |||||
| N | 168 | 14 | 87.14 | — | — | 56 | 61.44 | — | — | ||
| Y | 183 | 6 | 33.39 | — | — | 32 | 28.77 | — | — | ||
| Group 4 | TC/CC | TC/CC | 1.37 (0.26-7.35) | — | 0.76 (0.4-1.44) | — | |||||
| N | 90 | 3 | 33.88 | — | — | 24 | 46.23 | — | — | ||
| Y | 70 | 3 | 43.59 | — | — | 17 | 39.84 | — | — | ||
— indicates not applicable.
Expressed as n/1000/y.
Hazard ratios and confidence interval for effect of HT after adjustment for age, race, hypertension, diabetes, creatinine clearance, waist-to-hip ratio, and aspirin and statin use at baseline.
P value for HT*genotype interaction after adjustment for age, race, hypertension, diabetes, creatinine clearance, waist-to-hip ratio, and aspirin and statin use at baseline.